Zipalertinib Extends PFS in REZILIENT3

Company Taiho Pharmaceutical and Cullinan Therapeutics Event Type Clinical Trial Results (Phase III) Modality Oral Small-Molecule EGFR Exon 20 Insertion-Selective Inhibitor Asset Zipalertinib (CLN-081 / TAS6417) Target EGFR Exon 20 Insertion Variants Disease Area First-Line EGFR Exon 20 Insertion-Positive Advanced Non-Small Cell Lung Cancer Summary…